Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
14.30
+0.13 (0.92%)
At close: Oct 30, 2025, 4:00 PM EDT
14.40
+0.10 (0.70%)
After-hours: Oct 30, 2025, 5:49 PM EDT
Theravance Biopharma Stock Forecast
Stock Price Forecast
The 4 analysts that cover Theravance Biopharma stock have a consensus rating of "Strong Buy" and an average price target of $23, which forecasts a 60.84% increase in the stock price over the next year. The lowest target is $15 and the highest is $28.
Price Target: $23 (+60.84%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 12, 2025.
Analyst Ratings
The average analyst rating for Theravance Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +95.80% | Sep 12, 2025 |
| BTIG | BTIG | Strong Buy Maintains $24 → $25 | Strong Buy | Maintains | $24 → $25 | +74.83% | Jun 27, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +67.83% | Jun 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +4.90% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +4.90% | Feb 25, 2025 |
Financial Forecast
Revenue This Year
115.77M
from 64.38M
Increased by 79.82%
Revenue Next Year
106.20M
from 115.77M
Decreased by -8.27%
EPS This Year
0.94
from -1.15
EPS Next Year
-0.26
from 0.94
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 163.9M | 187.1M | |||
| Avg | 115.8M | 106.2M | |||
| Low | 93.6M | 70.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 154.5% | 61.6% | |||
| Avg | 79.8% | -8.3% | |||
| Low | 45.4% | -38.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.99 | 0.08 | |||
| Avg | 0.94 | -0.26 | |||
| Low | 0.88 | -0.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | -91.1% | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.